Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, Sinopharm Group Wuhan Biological Products Co., Ltd., has developed...
According to the Zhituo Finance APP, Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary, Wuhan Biological Products Co., Ltd. of China National Pharmaceutical Group, has developed "Intravenous COVID-19 Human Immunoglobulin (pH4)" which is currently in Phase II clinical trial research. Recently, after a comprehensive evaluation, the company has decided to terminate the Phase II clinical trial research and subsequent development of this drug.
It is reported that the total research and development investment in Intravenous COVID-19 Human Immunoglobulin (pH4) amounts to 120.607 million yuan, including research and development costs and equipment purchase costs. Among them, the cumulative research and development costs total 116.9095 million yuan, with 116.9099 million yuan accounted for in previous fiscal periods, and -0.0004 million yuan projected for the 2024 fiscal period. The company's termination of the clinical trial and subsequent research and development of Intravenous COVID-19 Human Immunoglobulin (pH4) will not have a significant impact on the company's future production operations and performance.
